Table 2.
HR-HPV Prevalence at Enrollment and Follow up
| Study visit and number of HR-HPV infections | Intervention | Control | Prevalence risk ratio of HR- HPV infection, intervention/control (referent no HR-HPV) (95%CI) | ||
|---|---|---|---|---|---|
| HR-HPV | % | HR-HPV | % | ||
| Enrollment | N = 97* | N = 94* | |||
| No HR-HPV | 27 | 23.4 | 22 | 27.8 | |
| One or more HR-HPV infection | 70 | 72.2 | 72 | 76.6 | 0.94 (0.80–1.11) |
| Single HR-HPV infection | 22 | 22.7 | 27 | 28.7 | 0.79 (0.49–1.28) |
| Multiple HR-HPV infections | 48 | 49.5 | 45 | 47.9 | 1.03 (0.77–1.38) |
| 24 Months | N = 85* | N = 106* | |||
| No HR-HPV | 38 | 44.7 | 30 | 28.3 | |
| One or more HR-HPV infection | 47 | 55.3 | 76 | 71.7 | 0.77 (0.62–0.97) |
| Single HR-HPV infection | 28 | 32.9 | 31 | 29.2 | 1.13 (0.74–1.72) |
| Multiple HR-HPV infections | 19 | 22.4 | 45 | 42.5 | 0.53 (0.33–0.83) |
*
The denominators are samples will amplifiable cellular or viral DNA. At enrollment, 6 intervention and 13 control samples had non-amplifiable viral and cellular DNA, and at 24 months, 8 intervention and 1 control samples had unamplifiable DNA.